Since risks and monitoring needs vary by individual and by GLP-1 drug, you should rely on your clinician for personalized guidance and instructions
Approximately one-third (33.2%) of those who received semaglutide 7.2 achieved 25% weight loss after 72 weeks, compared with 16.7% for semaglutide 2.4 mg and 0% for placebo
To be considered a candidate for receiving one of these medications for weight loss, a person typically must have a body mass index (BMI) indicating obesity, or a lower BMI if they are already experiencing complications due to their body weight (such as type 2 diabetes, high blood pressure, or high cholesterol)
For many, the risks are vastly outweighed by the benefits: The medication is FDA approved and considered safe to use for weight loss for most people
Any compounded medication fee filled for patients is nonrefundable
What gauge needle is generally recommended for GHK-Cu administration